Technology | July 11, 2014

Cordis Launches Saber PTA Dilatation Balloon for Peripheral Arterial Disease


July 11, 2014 — Cordis Corp. announced the launch of its Saber PTA (percutaneous transluminal angioplasty) dilatation catheter for the treatment of patients with peripheral arterial disease (PAD). The Saber catheter is cleared for use and now available in Europe, the United States and Japan. This new product offers crossability and a comprehensive offering of balloon sizes on the widely used 0.018-inch over-the-wire (OTW) platform.

Developed to complement the Cordis PTA portfolio as a next-generation, high-performance workhorse 0.018-inch PTA balloon catheter, Saber is intended to dilate stenoses in iliac, femoral, ilio-femoral, popliteal, infrapopliteal and renal arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. The device is also indicated for post-dilation of balloon-expandable and self-expanding stents in the peripheral vasculature.

Saber is available in balloon diameters of 2-10 mm and lengths of 20-300 mm. It combines a durable dual layer hydrophilic coating with a low-profile body and new molded tip design to enhance crossability. The catheter has exceptional rated burst pressures of up to 18 atm due to its construction with Duralyn material

“In my initial experience with Saber catheter, I see outstanding crossability in very tight lesions as well as excellent deflation times,” said Peter Goverde, M.D., ZNA Antwerpen in Brussels, Belgium. “Given these performance characteristics combined with the size offering that Saber catheter provides, I see the value in adopting this as the preferred 0.018-inch workhorse balloon in my practice.”

“Saber catheter is the third new product launch from Cordis in the PAD space in the past 12 months, expanding our existing high-performance lower extremity portfolio, including the S.M.A.R.T. stent vascular line of products, such as our unique S.M.A.R.T. flex stent, and the highly differentiated specialty Chocolate balloon catheter,” said Celine Martin, president of Cordis. ”With the addition of both the Chocolate balloon catheter and extensive line of Saber catheter products, we’ve strengthened and deepened our overall offering in both the specialty and workhorse PTA segments.”

For more information: www.cordis.com


Related Content

News | Balloon Catheter

June 13, 2024 — The U.S. Food and Drug Administration (FDA) announced that Teleflex, and their subsidiary Arrow ...

Home June 13, 2024
Home
News | Balloon Catheter

April 4, 2024 — The U.S. Food and Drug Administration (FDA) announced that Medos International Sàrl is recalling ...

Home April 04, 2024
Home
News | Balloon Catheter

January 18, 2024 — Summa Therapeutics, LLC announced that the first-in-man injectable angioplasty procedures for ...

Home January 18, 2024
Home
News | Balloon Catheter
Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional ...
Home February 25, 2022
Home
News | Balloon Catheter

February 15, 2022 – CERENOVUS, an emerging leader in neurovascular care and part of Johnson & Johnson Medical Devices ...

Home February 15, 2022
Home
News | Balloon Catheter

May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated ...

Home May 20, 2021
Home
Feature | Balloon Catheter | By Dave Fornell, Editor

The first devices developed for interventional cardiology were percutaneous transluminal coronary angioplasty (PTCA) ...

Home March 16, 2021
Home
Feature | Balloon Catheter

February 17, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Shockwave Medical's Intravascular ...

Home February 17, 2021
Home
News | Balloon Catheter

June 4, 2020 — Transit Scientific announced the U.S. Food and Drug Administration (FDA) cleared the XO Score ...

Home June 04, 2020
Home
News | Balloon Catheter

February 24, 2020 — Abbott has voluntarily recalled specific lots of two types of its coronary angioplasty catheters — ...

Home February 24, 2020
Home
Subscribe Now